GlassScriptPhysician profile
Ahmad Mahadeen
NPI 1538689468
$3,034.04
in general payments reported to CMS, 2019-2025
12 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2021: $58.31 · 2022: $996 · 2023: $478 · 2024: $744 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $520.24 | 2022-2025 | |
| Sk Life Science, INC. | $474.08 | 2022-2025 | Xcopri |
| Biogen, INC. | $397.09 | 2021-2025 | Vumerity |
| Ucb, INC. | $368.37 | 2023-2025 | Nayzilam, Briviact, Fintepla |
| Jazz Pharmaceuticals INC. | $332.49 | 2022-2023 | |
| Genzyme Corporation | $311.78 | 2019-2025 | |
| Amgen INC. | $155.24 | 2024-2025 | Uplizna |
| Celgene Corporation | $129.21 | 2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $124.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $99.00 | 2022 | |
| Genentech USA, INC. | $85.03 | 2025 | Ocrevus Zunovo |
| Emd Serono, INC. | $36.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Mahadeen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.